Purposenon-standard AAV2 rep-AAV-PHP.V2 cap plasmid with AAV cap expression controlled by a tTA-TRE amplification system
|Item||Catalog #||Description||Quantity||Price (USD)|
|Plasmid||127848||Standard format: Plasmid sent in bacteria as agar stab||1||$85|
This material is available to academics and nonprofits only.
- Backbone size w/o insert (bp) 6314
Vector typeMammalian Expression, AAV
Growth in Bacteria
Bacterial Resistance(s)Ampicillin, 100 μg/mL
Growth Strain(s)NEB Stable
Gene/Insert nameSynthetic construct isolate AAV-PHP.V2 VP1 gene
Alt nameAAV-PHP.V2 Cap
Insert Size (bp)2229
- Promoter p41
- Cloning method Gibson Cloning
Terms and Licenses
- Not Available to Industry
- Zeocin® is an InvivoGen trademark.
Please note that this is a non-standard rep-cap construct. It uses a tTA-TRE amplification loop to increase Capsid expression and AAV production. We find that this system increases AAV titers 1.5-5 fold (Ben Deverman, Bryan Simpson and Paul Patterson, unpublished data). This is a tet-off system, so no dox or tet is needed to turn it on. It can be used like any other rep-cap plasmid. This system should only present a problem if the rAAV genome to be packaged has a tet responsive element that directs expression of a protein that affected the health of the production cells.
These plasmids were created by your colleagues. Please acknowledge the Principal Investigator, cite the article in which the plasmids were described, and include Addgene in the Materials and Methods of your future publications.
For your Materials & Methods section:pUCmini-iCAP-PHP.V2 was a gift from Viviana Gradinaru (Addgene plasmid # 127848 ; http://n2t.net/addgene:127848 ; RRID:Addgene_127848)
For your References section:Multiplexed Cre-dependent selection yields systemic AAVs for targeting distinct brain cell types. Ravindra Kumar S, Miles TF, Chen X, Brown D, Dobreva T, Huang Q, Ding X, Luo Y, Einarsson PH, Greenbaum A, Jang MJ, Deverman BE, Gradinaru V. Nat Methods. 2020 May;17(5):541-550. doi: 10.1038/s41592-020-0799-7. Epub 2020 Apr 20. 10.1038/s41592-020-0799-7 PubMed 32313222